Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets

Stock Information for Longeveron Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Longeveron Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.